Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$77.89
-1.5%
$69.14
$14.30
$82.26
$10.98B1.282.48 million shs671,650 shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$23.75
-1.0%
$22.98
$13.09
$27.72
$11.89B1.695.40 million shs4.28 million shs
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
$25.28
+3.3%
$23.48
$7.91
$28.72
$3.18B0.871.19 million shs1.44 million shs
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$13.66
+1.0%
$13.44
$12.19
$16.17
$11.40B0.272.26 million shs707,355 shs
7 Stocks to Buy And Hold Forever Cover

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
+0.08%+4.65%+12.69%+24.94%+408.03%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
+0.99%+12.37%+7.85%-9.16%+78.79%
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
+1.90%+3.00%-0.80%+20.48%+169.75%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
-0.43%+0.09%-3.49%-5.70%-7.15%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$77.89
-1.5%
$69.14
$14.30
$82.26
$10.98B1.282.48 million shs671,650 shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$23.75
-1.0%
$22.98
$13.09
$27.72
$11.89B1.695.40 million shs4.28 million shs
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
$25.28
+3.3%
$23.48
$7.91
$28.72
$3.18B0.871.19 million shs1.44 million shs
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$13.66
+1.0%
$13.44
$12.19
$16.17
$11.40B0.272.26 million shs707,355 shs
7 Stocks to Buy And Hold Forever Cover

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
+0.08%+4.65%+12.69%+24.94%+408.03%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
+0.99%+12.37%+7.85%-9.16%+78.79%
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
+1.90%+3.00%-0.80%+20.48%+169.75%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
-0.43%+0.09%-3.49%-5.70%-7.15%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
2.75
Moderate Buy$87.8012.73% Upside
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.77
Moderate Buy$28.2018.74% Upside
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
2.55
Moderate Buy$33.8934.05% Upside
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
2.00
Hold$16.9023.76% Upside

Current Analyst Ratings Breakdown

Latest RCUS, RDY, ELAN, and ARWR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/20/2026
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
DowngradeHold (C-)Sell (D-)
5/18/2026
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
Initiated CoverageBuy$30.00 ➝ $35.00
5/13/2026
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
Boost Price TargetMarket Perform$35.00 ➝ $46.00
5/12/2026
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
DowngradeHold (C+)Hold (C)
5/11/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
DowngradeSell (D+)Sell (D)
5/11/2026
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
Boost Price TargetEqual Weight$20.00 ➝ $22.00
5/8/2026
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
Boost Price TargetOutperform$80.00 ➝ $87.00
5/7/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Boost Price TargetBuy$30.00 ➝ $31.00
5/7/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Boost Price TargetOverweight$28.00 ➝ $30.00
5/7/2026
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
Boost Price TargetBuy$30.00 ➝ $34.00
5/6/2026
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
Reiterated RatingHold (C-)
(Data available from 5/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$829.45M13.23$0.12 per share661.56$4.25 per share18.33
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.72B2.52$2.33 per share10.21$13.01 per share1.83
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
$247M12.87N/AN/A$4.17 per share6.06
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$3.58B3.18$0.87 per share15.75$5.15 per share2.65
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-$1.63M-$2.15N/AN/AN/A-48.38%-55.09%-18.13%8/6/2026 (Estimated)
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-$232M-$0.50N/A19.632.55-4.95%7.42%3.66%8/6/2026 (Estimated)
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
-$353M-$3.18N/AN/AN/A-156.36%-68.97%-35.27%8/5/2026 (Estimated)
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$484.20M$0.5823.5422.021.8812.90%12.16%8.12%7/22/2026 (Estimated)

Latest RCUS, RDY, ELAN, and ARWR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2026Q4 25/26
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$0.09$0.06-$0.03-$0.03$886.58 million$852.55 million
5/7/2026Q2 2026
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-$1.0950-$0.93+$0.1650-$0.93$73.84 million$73.74 million
5/6/2026Q1 2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.34$0.40+$0.06$0.11$1.28 billion$1.37 billion
5/5/2026Q1 2026
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
-$0.92-$1.02-$0.10-$1.02$29.49 million$17.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
N/AN/AN/AN/AN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
N/AN/AN/AN/AN/A
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$0.070.51%+6.96%12.07%N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
1.41
6.23
6.23
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.60
2.16
1.12
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
0.19
4.04
4.04
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
0.03
1.80
1.35

Institutional Ownership

CompanyInstitutional Ownership
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
62.61%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
97.48%
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
92.89%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
3.85%
CompanyEmployeesShares OutstandingFree FloatOptionable
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
400140.86 million135.79 millionOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,400499.45 million493.76 millionOptionable
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
500125.77 million113.70 millionOptionable
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
27,811834.65 million817.96 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Arrowhead Pharmaceuticals stock logo

Arrowhead Pharmaceuticals NASDAQ:ARWR

$77.89 -1.17 (-1.47%)
As of 03:21 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$23.75 -0.23 (-0.96%)
As of 03:21 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Arcus Biosciences stock logo

Arcus Biosciences NYSE:RCUS

$25.28 +0.80 (+3.27%)
As of 03:21 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Dr. Reddy's Laboratories stock logo

Dr. Reddy's Laboratories NYSE:RDY

$13.66 +0.14 (+1.00%)
As of 03:20 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.